%0 Observational Study
%T 18F-FDG-PET/CT response after first-line treatment as a prognostic factor for survival in peripheral T-cell lymphoma: a Spanish retrospective study.
%A Cordoba R
%A Sánchez-García J
%A Domingo-Domenech E
%A López Jiménez J
%A Martínez Pozo A
%A Carpio C
%A Bendaña Á
%A González AJ
%A González de Villambrosia S
%A Gómez Codina J
%A Navarro B
%A Rodríguez G
%A Naves A
%A Baeza L
%A Martín García-Sancho A
%J Expert Rev Hematol
%V 17
%N 1
%D 2024 Jan-Mar 7
%M 38299464
%F 2.819
%R 10.1080/17474086.2024.2313457
%X <B>UNASSIGNED: </B>An accurate assessment of tumor viability after first-line treatment is critical for predicting treatment failure in peripheral T-cell lymphomas (PTCLs). 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) has been adopted as the preferred assessment method in clinical trials, but its impact in clinical practice should be examined. This study aims to determine the prognostic significance of18F-FDG-PET/CT for survival following first-line treatment in PTCL patients.<BR><B>UNASSIGNED: </B>Retrospective observational study including 175 patients diagnosed with PTCL between 2008 and 2013 in 13 Spanish sites.<BR><B>UNASSIGNED: </B>Fifty patients were evaluated with18F-FDG-PET/CT following first-line therapy: 58% were18F-FDG-PET/CT-negative and 42% were18F-FDG-PET/CT-positive. Disease progression occurred in 37.9% of18F-FDG-PET/CT-negative patients and in 80.9% of18F-FDG-PET/CT-positive patients (p = 0.0037). Median progression-free survival and overall survival were 67 and 74 months for18F-FDG-PET/CT-negative patients, and 5 (p < 0.0001) and 10 months (p < 0.0001), respectively, in18F-FDG-PET/CT-positive patients. After multivariate analysis, only B symptoms emerged as a negative predictive factor of complete response (RR 7.08; 95% CI 1.60-31.31; p = 0.001).<BR><B>UNASSIGNED: </B>18F-FDG-PET/CT identifies high-risk PTCL patients who will have poor prognosis and survival following first-line treatment. However, more research is needed to confirm the best treatment options for PTCL patients.